Treating Heart Disease Behind Sudden Death in Young People | David Elsey

Cardiol Therapeutics is advancing its Phase 3 MAVERIC trial for recurrent pericarditis and reporting positive Phase 2 ARCHER data for myocarditis.

The company is strategically transitioning from rare cardiac diseases toward significantly larger commercial opportunities in the broader heart failure market.

A strong balance sheet provides the financial runway needed to support the company through key clinical milestones and upcoming regulatory submissions.